New treatment approach for cystic fibrosis using carbon monoxide
HBI-002 for Cystic Fibrosis
This study is exploring a new way to help people with cystic fibrosis by using small amounts of carbon monoxide to calm lung inflammation while keeping their immune system strong, aiming to make breathing easier and improve their overall quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hillhurst Biopharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Montrose, United States) |
| Project ID | NIH-10919079 on NIH RePORTER |
What this research studies
This research investigates a novel treatment for cystic fibrosis (CF) that utilizes low doses of carbon monoxide (CO) to reduce inflammation in the lungs without compromising immune function. The study builds on previous findings that demonstrated the safety and efficacy of CO in preclinical models and aims to develop a more viable therapeutic option for CF patients. By addressing the limitations of existing treatments, such as inhaled CO gas and CO-releasing molecules, this research seeks to improve lung function and quality of life for individuals suffering from CF.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with cystic fibrosis and experiencing chronic lung inflammation.
Not a fit: Patients with cystic fibrosis who are not adults or those with severe comorbidities that preclude participation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment that significantly improves lung function and quality of life for cystic fibrosis patients.
How similar studies have performed: Previous studies have shown success with low-dose carbon monoxide in treating pulmonary conditions, indicating a promising avenue for this novel approach in cystic fibrosis.
Where this research is happening
Montrose, United States
- Hillhurst Biopharmaceuticals, INC. — Montrose, United States (Active)
Researchers
- Principal investigator: Gomperts, Edward — Hillhurst Biopharmaceuticals, INC.
- Study coordinator: Gomperts, Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.